# Legend Biotech share price today (Legend Biotech Corporation, LEGN)

> Legend Biotech Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LEGN · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/legn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $22.54 (−29.1% in a year)
- Revenue (Jun 2026): $388 M (+51.9% on a year ago)
- Profit (Jun 2026): $33.2 M
- Operating margin: 14.9% (+23.5 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Legend Biotech share price today? Legend Biotech Corporation's share price was $22.54 at the close on 5 November 2026. It has been stalling near its high for 1 week. That is 1.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $17 and $36, and at that close it sat 30% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 6.4 years the share price moved −41% while the S&P 500 moved +141%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Legend Biotech pay? Legend Biotech Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Legend Biotech on? Legend Biotech is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Legend Biotech profitable? Legend Biotech Corporation earned $33.2 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $297 M. That is 8.6% of the quarter's revenue. The same quarter a year earlier lost $125 M. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Legend Biotech make, and is it growing? Legend Biotech Corporation reported $388 M of revenue in the Jun 2026 quarter, +51.9% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 4 years it has grown 96.6% a year on average. The last full year, FY25, came in at $1.0 B. The last four reported quarters add to $1.3 B. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $1.0 B, +64.0% on the year before. Recent pace: the last four quarters grew +60.6% on average, against 96.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +59.5%, against +67.0% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Legend Biotech keep? Legend Biotech Corporation's operating margin was 14.9% in the Jun 2026 quarter, 23.5 percentage points higher than the same quarter a year ago. Across 5 years it has been between −572.5% and −13.3%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +23.5 percentage points on the year while gross margin changed +2.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Legend Biotech's profit turning into cash? Legend Biotech Corporation's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $100 M of cash, against −$297 M of profit. After $28.6 M of spending on assets, free cash was −$129 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Legend Biotech's cash go? Legend Biotech Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $62.8 M on assets over the last 3 years. Averaged over those years that is 2.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $62.8 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Legend Biotech's P/E ratio, and how does it compare with its own history? Legend Biotech Corporation has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Legend Biotech Corporation at 4.2× its FY25 revenue of $1.0 B. The P/E comes back here once profit turns positive. ## Is the Legend Biotech business getting better or worse? Legend Biotech Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Legend Biotech earn on its capital? Legend Biotech Corporation earned a ROE of −30% in FY25. That is up from a low of −60% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −9,434%, a number that says nothing useful about the business. It comes from a −28.8% net margin and 0.59× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −28.8% net margin × 0.59× asset turnover × 1.73× leverage (assets divided by equity) ≈ −29.4% on equity. The margin does its share; borrowing is a big part of it. ## Does Legend Biotech have too much debt? Legend Biotech Corporation has total debt of $278 M against shareholder equity of $1.2 B as of Jun 2026, so its debt is 0.23× its equity, which is very little. Year by year, that ratio went from 0.16 in FY21 to 0.41 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Legend Biotech shareholding pattern? We have no ownership or short-position figures for Legend Biotech Corporation, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 6.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Legend Biotech from balance-sheet trouble? For Legend Biotech Corporation, the Z-score is 5.57. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 5.57 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Legend Biotech rank in its industry? There is no score against its industry: Legend Biotech Corporation is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Legend Biotech compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Legend Biotech in size? Legend Biotech is the 47th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: CRISPR Therapeutics AG, Travere Therapeutics, Inc. and Dianthus Therapeutics, Inc. Just below it: Catalyst Pharmaceuticals, Inc., Relay Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. ### Biotechnology companies close in size

1. [CRISPR Therapeutics AG](https://www.sectoralpha.in/us/stocks/crsp) $4.7 billion
2. [Travere Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tvtx) $4.7 billion
3. [Dianthus Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/dnth) $4.6 billion
4. Legend Biotech Corporation $4.4 billion
5. [Catalyst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/cprx) $3.9 billion
6. [Relay Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rlay) $3.7 billion
7. [ACADIA Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/acad) $3.7 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [CorVel Corporation](https://www.sectoralpha.in/us/stocks/crvl) $4.4 billion · Insurance Brokers
2. [Solaris Energy Infrastructure, Inc.](https://www.sectoralpha.in/us/stocks/sei) $4.4 billion · Oil & Gas Equipment & Services
3. Legend Biotech Corporation $4.4 billion
4. [Mirion Technologies, Inc.](https://www.sectoralpha.in/us/stocks/mir) $4.4 billion · Specialty Industrial Machinery
5. [Flagstar Bank, National Association](https://www.sectoralpha.in/us/stocks/flg) $4.4 billion · Banks - Regional

## What else do people ask about Legend Biotech? ### What were Legend Biotech's latest quarterly results? Legend Biotech Corporation reported revenue of $388 M and net profit of $33.2 M for the Jun 2026 quarter. Earnings per share were $0.18. The operating margin was 14.9%, 23.5 percentage points higher than a year earlier (as of 5 November 2026). ### What is Legend Biotech's market cap? Legend Biotech Corporation's market capitalisation is $4.4 B at a stock price of $22.54. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Legend Biotech performing? Legend Biotech Corporation's share price has been stalling near its high for 1 weeks. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Legend Biotech's stock price go up? This page does not forecast Legend Biotech Corporation's stock price. What it shows instead: the stock price is $22.54, and it has been stalling near its high for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Legend Biotech in its business cycle? Legend Biotech Corporation's FY25 operating margin was −13.3%, against a 5-year range of −572.5% to −13.3%: the middle of its own range, neither a peak nor a low. The latest quarter was 14.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Legend Biotech story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Legend Biotech a stock worth studying right now? What the numbers show: Legend Biotech Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.